Literature DB >> 21770423

Hepatocellular carcinoma cells and their fibrotic microenvironment modulate bone marrow-derived mesenchymal stromal cell migration in vitro and in vivo.

Mariana G Garcia1, Juan Bayo, Marcela F Bolontrade, Leonardo Sganga, Mariana Malvicini, Laura Alaniz, Jorge B Aquino, Esteban Fiore, Manglio M Rizzo, Andrés Rodriguez, Alicia Lorenti, Oscar Andriani, Osvaldo Podhajcer, Guillermo Mazzolini.   

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the third cause of cancer-related death. Fibrogenesis is an active process characterized by the production of several proinflammatory cytokines, chemokines and growth factors. It involves the activation of hepatic stellate cells (HSCs) which accumulate at the site of injury and are the main source of the extracellular matrix deposits. There are no curative treatments for advanced HCC, thus, new therapies are urgently needed. Mesenchymal stromal cells (MSCs) have the ability to migrate to sites of injury or to remodeling tissues after in vivo administration; however, in several cancer models they demonstrated limited efficacy to eradicate experimental tumors partially due to poor engraftment. Thus, the aim of this work was to analyze the capacity of human MSCs (hMSCs) to migrate and anchor to HCC tumors. We observed that HCC and HSCs, but not nontumoral stroma, produce factors that induce hMSC migration in vitro. Conditioned media (CM) generated from established HCC cell lines were found to induce higher levels of hMSC migration than CM derived from fresh patient tumor samples. In addition, after exposure to CM from HCC cells or HSCs, hMSCs demonstrated adhesion and invasion capability to endothelial cells, type IV collagen and fibrinogen. Consistently, these cells were found to increase metalloproteinase-2 activity. In vivo studies with subcutaneous and orthotopic HCC models indicated that intravenously infused hMSCs migrated to lungs, spleen and liver. Seven days post-hMSC infusion cells were located also in the tumor in both models, but the signal intensity was significantly higher in orthotopic than in subcutaneous model. Interestingly, when orthotopic HCC tumors where established in noncirrhotic or cirrhotic livers, the amount of hMSCs localized in the liver was higher in comparison with healthy animals. A very low signal was found in lungs and spleens, indicating that liver tumors are able to recruit them at high efficiency. Taken together our results indicate that HCC and HSC cells produce factors that efficiently induce hMSC migration toward tumor microenvironment in vitro and in vivo and make MSCs candidates for cell-based therapeutic strategies to hepatocellular carcinoma associated with fibrosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21770423     DOI: 10.1021/mp200137c

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  30 in total

1.  Hyperfibrinogenemia predicts poor prognosis in patients with advanced biliary tract cancer.

Authors:  Heming Li; Tong Zhao; Xuening Ji; Shanshan Liang; Zhe Wang; Yulong Yang; Jiajun Yin; Ruoyu Wang
Journal:  Tumour Biol       Date:  2015-10-09

2.  Combining stem cells and genes for effective therapeutics.

Authors:  Zhaoyang Ye; Ram I Mahato
Journal:  Mol Pharm       Date:  2011-10-03       Impact factor: 4.939

3.  A specific subpopulation of mesenchymal stromal cell carriers overrides melanoma resistance to an oncolytic adenovirus.

Authors:  Marcela F Bolontrade; Leonardo Sganga; Eduardo Piaggio; Diego L Viale; Miguel A Sorrentino; Aníbal Robinson; Gustavo Sevlever; Mariana G García; Guillermo Mazzolini; Osvaldo L Podhajcer
Journal:  Stem Cells Dev       Date:  2012-05-14       Impact factor: 3.272

4.  Inflammatory Chemokines MIP-1δ and MIP-3α Are Involved in the Migration of Multipotent Mesenchymal Stromal Cells Induced by Hepatoma Cells.

Authors:  Esma Lejmi; Nadja Perriraz; Sophie Clément; Philippe Morel; Reto Baertschiger; Panayiotis Christofilopoulos; Raphael Meier; Domenico Bosco; Léo H Bühler; Carmen Gonelle-Gispert
Journal:  Stem Cells Dev       Date:  2015-03-03       Impact factor: 3.272

5.  IMT504 blocks allodynia in rats with spared nerve injury by promoting the migration of mesenchymal stem cells and by favoring an anti-inflammatory milieu at the injured nerve.

Authors:  Mailín Casadei; Esteban Fiore; Julia Rubione; Luciana María Domínguez; María Florencia Coronel; Candelaria Leiguarda; Mariana García; Guillermo Mazzolini; Marcelo J Villar; Alejandro Montaner; Luis Constandil; E Alfonso Romero-Sandoval; Pablo R Brumovsky
Journal:  Pain       Date:  2021-09-15       Impact factor: 7.926

6.  Connective tissue growth factor is overexpressed in human hepatocellular carcinoma and promotes cell invasion and growth.

Authors:  Ming Xiu; Ya-Hui Liu; David R Brigstock; Fang-Hui He; Rui-Juan Zhang; Run-Ping Gao
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

7.  Mesenchymal stromal cells engineered to produce IGF-I by recombinant adenovirus ameliorate liver fibrosis in mice.

Authors:  Esteban J Fiore; Juan M Bayo; Mariana G Garcia; Mariana Malvicini; Rodrigo Lloyd; Flavia Piccioni; Manglio Rizzo; Estanislao Peixoto; M Beatriz Sola; Catalina Atorrasagasti; Laura Alaniz; María A Camilletti; Mónica Enguita; Jesús Prieto; Jorge B Aquino; Guillermo Mazzolini
Journal:  Stem Cells Dev       Date:  2014-12-03       Impact factor: 3.272

Review 8.  Androgen receptor roles in hepatocellular carcinoma, fatty liver, cirrhosis and hepatitis.

Authors:  Wen-Lung Ma; Hsueh-Chou Lai; Shuyuan Yeh; Xiujun Cai; Chawnshang Chang
Journal:  Endocr Relat Cancer       Date:  2014-05-06       Impact factor: 5.678

9.  Inhibitory effect of endostar on specific angiogenesis induced by human hepatocellular carcinoma.

Authors:  Qing Ye; Shukui Qin; Yanhong Liu; Jundong Feng; Qiong Wu; Wenshu Qu; Xiaojin Yin
Journal:  Gastroenterol Res Pract       Date:  2015-04-23       Impact factor: 2.260

Review 10.  Mesenchymal Stem Cells Engineered by Nonviral Vectors: A Powerful Tool in Cancer Gene Therapy.

Authors:  Yuan Ding; Chenyang Wang; Zhongquan Sun; Yingsheng Wu; Wanlu You; Zhengwei Mao; Weilin Wang
Journal:  Pharmaceutics       Date:  2021-06-21       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.